Diagnosis and treatment of malignant neoplasms
AssigneeRhode Island Hospital
InventorsJack R. Wands, Suzanne M. de la Monte, Nedim Ince, Rolf I. Carlson
Life of this patent
Estimating the term…
Abstract
The invention features a method for diagnosing a malignant neoplasm in a mammal by contacting a bodily fluid from the mammal with an antibody which binds to an human aspartyl (asparaginyl) beta-hydroxylase (HAAH) polypeptide and methods of treating malignant neoplasms by inhibiting HAAH.
Claims20
A monoclonal antibody that binds to an epitope within a catalytic domain of HAAH, said domain comprising residues 650-700 of SEQ ID NO:2.
A monoclonal antibody that binds to an epitope of SEQ ID NO:2, wherein said monoclonal antibody is selected from the group consisting of 5C7 produced by hybridoma ATCC designation PTA 3383, 19B produced by hybridoma ATCC designation 3384, and 86A produced by hybridoma ATCC designation 3385.
A monoclonal antibody 5C7 produced by hybridoma ATCC designation PTA 3383.
A monoclonal antibody 19B produced by hybridoma ATCC designation 3384.
A monoclonal antibody 86A produced by hybridoma ATCC designation 3385.
A monoclonal antibody FB501 produced by hybridoma ATCC designation 3386.
A fragment of a monoclonal antibody that binds to an epitope of SEQ ID NO:2, wherein said antibody is a is produced by hybridoma ATCC designation PTA 3386.
A composition comprising, a fragment of an antibody produced by hybridoma ATCC designation PTA3386. said fragment being linked to a cytotoxic agent.
A kit for diagnosis of a tumor in a mammal, comprising a monoclonal antibody that binds to an epitope within a catalytic domain of HAAH, said catalytic domain comprising residues 650-700 of SEQ ID NO:2.
Dependencies are inferred from the claim text.